Navigation Links
CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer

Clinic to Serve as rEEG(R) 'Center of Excellence' Advancing Performance in

Patient Outcomes, Costs and Convenience

COSTA MESA, Calif., Jan. 15 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that it has completed the previously announced acquisition of Neuro-Therapy Clinic, P.C., a neuropsychiatric clinic in Denver, Colorado. The Company also announced that Daniel A. Hoffman, MD has been appointed Chief Medical Officer. Dr. Hoffman, a neuropsychiatrist with more than 25 years experience, was previously National Medical Director of Neuro-Therapy Clinic.

Len Brandt, Chairman and CEO of CNS Response, reported, "Our close relationship with Dr. Hoffman and the Neurotherapy Clinic has already played a significant role in establishing the value of rEEG(R) guidance in medication management."

George Carpenter, President of CNS Response, commenting on the future, said, "We expect Neuro-Therapy Clinic to further define the opportunity to use technology in general, and rEEG in particular, to vastly improve clinic performance in patient outcomes, costs, and convenience and to best communicate this to all -- patient, physician, payer. In this way, the Neuro-Therapy Clinic is something of a dynamic laboratory discovering how to integrate technology and be a true center of excellence on all of these measures. Put to practice, this knowledge presents CNS Response with an opportunity to further our relationship with other clinics and physicians using rEEG."

"Dr. Hoffman is a leader and a true partner in the development of rEEG so we are particularly pleased to have him join our team," Mr. Brandt continued. "Dr. Hoffman will play a critical role in implementing our strategy for the validation and commercialization of our core rEEG platform."

Established in 1993, Neuro-Therapy Clinic, P.C. is a center for highly-advanced testing and treatment of neuropsychiatric problems, including learning, attentional and behavioral challenges, mild head injuries, as well as depression, anxiety, bipolar and all other common psychiatric disorders.

Dr. Hoffman served as Medical Director for Neuro-Therapy Clinic from 1993-2007. He also served as National Medical Director for CNS Response from 2004-2007 and has maintained a private practice in neuropsychiatry since 1977. He served as an Assistant Clinical Professor at the University of Colorado from 1977 to 1996.

Dr. Hoffman has lectured extensively throughout the country on leading-edge testing and treatment for Psychiatric Medication Selection and other brain related topics and has been published in more than 30 peer-reviewed articles. He is on the editorial boards of the Journal of Neurotherapy, the Journal of Applied Psychophysiology and Self Regulation and the Journal of Neuropsychiatry and Clinical Neurosciences.

About CNS Response

CNS Response is a life-sciences data company focused on the commercialization of the first patented commercial system that guides psychiatrists and other physicians to determine proper treatments for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aide to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.


Investor Relations:

Sara Ephraim

(646) 536-7002


Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CNS Response, Inc. Announces Acquisition of Neuropsychiatric Clinic
2. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
3. China Medical Technologies Completes Acquisition of BBE
4. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
5. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
8. Edwards Lifesciences Completes Acquisition of CardioVations Product Line
9. Fovea Pharmaceuticals Completes EUR30M Series B Financing
10. Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing
11. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
Post Your Comments:
(Date:10/12/2015)... , ... October 12, 2015 , ... Spirax Sarco, the ... release of the CSM-C 600 compact clean steam generator . This unit ... meets the requirements of HTM2031, HTM2010, and EN285 standards. The CMS-C 600 generator ...
(Date:10/12/2015)... 12 de octubre de 2015 El 8 ... a un récord en el congreso con su declaración ... la International Plasma Awareness Week (IPAW), que se celebrará ... patrocinada por la Plasma Protein Therapeutics Association ... , Aumentar la concienciación mundial acerca de ...
(Date:10/12/2015)... NAMUR , Belgium , Oct. 12, ... today announced that full results from a completed clinical study ... pancreatic cancers have been published in the online issue of ... Epigenetics Society. The peer-reviewed study was conducted in collaboration with ... , and led by Roland Andersson , MD, PhD, ...
(Date:10/10/2015)... le 10 octobre 2015 Le 8 octobre, l,honorable ... le Registre du Congrès sa déclaration de soutien ... sensibilisation autour du plasma (IPAW), qui se tiendra ... la Plasma Protein Therapeutics Association (PPTA) ... , Sensibiliser l,opinion publique mondiale autour ...
Breaking Biology Technology:
(Date:10/2/2015)... DUBLIN , Oct. 02 2015 ... addition of the "Enforcing the Law Using ... ) has announced the addition of ... report to their offering. --> Research ... addition of the "Enforcing the Law Using ...
(Date:9/30/2015)... 30, 2015  The U.S. Court of Appeals for ... ruling in favor of Crossmatch ™, affirming the ... company Suprema and its U.S. partner Mentalix violated Section ... provision that declares it unlawful to engage in "unfair ... of Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 ...
(Date:9/29/2015)... excited to be named one of the first 100 IBM ... was recently made at an invite-only IBM Watson: Fueling ... , where iDAvatars presented a demo of its Intelligent ... is both an honor and a privilege to be one ... cognitive power of IBM Watson in our product, which empowers ...
Breaking Biology News(10 mins):